← Back to Screener
ResMed Inc. (RMD)
Price$224.72
Favorite Metrics
Price vs S&P 500 (26W)-22.95%
Price vs S&P 500 (4W)-5.42%
Market Capitalization$32.70B
P/E Ratio (Annual)23.35x
Indicated Dividend Yield (Annual)1.05%
All Metrics
P/CF (Annual)18.67x
Book Value / Share (Quarterly)$43.39
P/TBV (Annual)6.87x
Indicated Dividend (Annual)$2.40
Revenue Growth (3Y)12.88%
Cash Flow / Share (Quarterly)$12.20
Payout Ratio (TTM)22.25%
Price vs S&P 500 (YTD)-7.65%
Gross Margin (TTM)60.85%
Net Profit Margin (TTM)27.53%
EPS (TTM)$10.12
10-Day Avg Trading Volume0.91M
EPS Excl Extra (TTM)$10.12
Revenue Growth (5Y)11.72%
EPS (Annual)$9.51
Dividend / Share (Annual)$2.12
ROI (Annual)21.11%
Gross Margin (Annual)59.33%
Net Profit Margin (5Y Avg)21.38%
Cash / Share (Quarterly)$9.73
P/E Basic Excl Extra (TTM)22.01x
Revenue Growth QoQ (YoY)10.98%
EPS Growth (5Y)17.38%
P/E Normalized (Annual)23.35x
ROA (Last FY)17.14%
Revenue Growth TTM (YoY)9.57%
EBITD / Share (TTM)$12.60
ROE (5Y Avg)21.16%
Operating Margin (TTM)33.70%
Cash Flow / Share (Annual)$11.28
P/B Ratio5.17x
P/B Ratio (Quarterly)5.56x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)5.92x
Net Interest Coverage (TTM)661.20x
ROA (TTM)18.26%
EPS Growth QoQ (YoY)14.79%
EV / EBITDA (TTM)17.26x
EPS Incl Extra (Annual)$9.51
Current Ratio (Annual)3.44x
Quick Ratio (Quarterly)1.97x
3-Month Avg Trading Volume1.04M
52-Week Price Return6.65%
EV / Free Cash Flow (Annual)19.35x
P/E Incl Extra (TTM)22.01x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$40.44
P/S Ratio (Annual)6.35x
Asset Turnover (Annual)0.63x
52-Week High$293.81
Operating Margin (5Y Avg)28.89%
EPS Excl Extra (Annual)$9.51
CapEx CAGR (5Y)-1.01%
Tangible BV CAGR (5Y)21.85%
26-Week Price Return-18.97%
Quick Ratio (Annual)2.16x
13-Week Price Return-11.26%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)3.06x
Enterprise Value$31,948.649
Revenue / Share Growth (5Y)11.47%
Asset Turnover (TTM)0.66x
Book Value / Share Growth (5Y)18.79%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.39x
Pretax Margin (Annual)32.60%
Cash / Share (Annual)$8.26
3-Month Return Std Dev27.39%
Gross Margin (5Y Avg)57.21%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)15.86%
EBITDA Interim CAGR (5Y)17.05%
ROE (Last FY)23.47%
Net Interest Coverage (Annual)58.23x
EPS Basic Excl Extra (Annual)$9.51
P/FCF (TTM)18.41x
Receivables Turnover (TTM)5.53x
EV / Free Cash Flow (TTM)17.98x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$10.12
Receivables Turnover (Annual)5.52x
ROI (TTM)22.32%
Dividend Growth Rate (5Y)6.33%
P/S Ratio (TTM)6.06x
Pretax Margin (5Y Avg)28.03%
Revenue / Share (Annual)$34.93
Tangible BV / Share (Annual)$37.59
Forward P/E20.36x
Free OCF CAGR (5Y)18.84%
Price vs S&P 500 (52W)-23.18%
P/E Ratio (TTM)22.01x
EPS Growth TTM (YoY)19.51%
Year-to-Date Return-5.01%
5-Day Price Return0.36%
EPS Normalized (Annual)$9.51
ROA (5Y Avg)14.13%
Net Profit Margin (Annual)27.22%
Month-to-Date Return1.92%
Cash Flow / Share (TTM)$7.33
EBITD / Share (Annual)$11.71
EPS Growth (3Y)21.50%
Operating Margin (Annual)32.75%
LT Debt / Equity (Annual)0.11x
P/CF (TTM)17.08x
ROI (5Y Avg)17.56%
P/E Excl Extra (TTM)22.01x
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$10.12
P/TBV (Quarterly)5.97x
Payout Ratio (Annual)22.19%
P/B Ratio (Annual)6.34x
Dividend / Share (TTM)$2.26
Inventory Turnover (TTM)2.34x
Pretax Margin (TTM)33.69%
Book Value / Share (Annual)$40.77
Price vs S&P 500 (13W)-11.95%
Net Margin Growth (5Y)5.31%
Dividend Yield (TTM)1.01%
Beta0.93x
P/FCF (Annual)19.81x
Revenue / Share (TTM)$36.88
ROE (TTM)24.81%
52-Week Low$202.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.72
3.72
3.72
3.68
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
GMEDGLOBUS MEDICAL INC | 4.34x | 30.08% | 67.41% | 20.33% | $92.76 |
About
ResMed is a global leader in respiratory care devices for sleep apnea treatment, with structural growth tailwinds from rising diagnoses, aging populations, and increasing obesity prevalence. The company generates approximately two-thirds of revenue from the Americas, with the remainder from Europe, Japan, and Australia. ResMed is building competitive differentiation through digital health platforms that deliver clinical data to patients, healthcare providers, and payers in out-of-hospital settings.